|
Tuesday December 5, 2006
|
 Please forgive the puddles of drool forming around my keyboard. While I've mostly learned to restrain myself in the face of shiny new gadgets, it's times like this that I wish I'd picked up one of those Unotron numbers, as the reams of smoke and sparks begin to issue forth, under my fingers. Sure the 80GB iPod was an exciting proposition, but as someone who can't walk down the street without every Pavement b-side and the complete recorded works of Leadbelly clipped to my belt, the prospect of a 100GB version of the device is enough reason to start eyeing that lump of cash we've been saving up for grandma's operation. Praise the lord, Toshiba's latest 1.8" hard disk, due out next month, may just be the manna from heaven we've been waiting for. Sorry, grandma, but the Coltrane collection is getting out of control.
[Via Akihabara News.]
|
|
|
Mixx It
Digg It
Stumble
More...
December 5, 2006 11:31 AM
Hey Brian,
Especially if you've imported CDs as Apple Lossless. Then you go through 80GB in a split second, and you get to listen to the iPod's CPU hiccup as it stumbles over starting new tracks.
December 5, 2006 4:07 PM
yeah, just what I need, a keychain pendant with more hard drive space than my poor abused 6 year old home computer. Well, I guess this is the clue that it's finally time to break into the bank and upgrade my dinosaur.
May 9, 2007 10:50 PM
On Friday, the first day after Merck's loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor's. In addition, Dr. Reddy's Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA's decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis' generic drug unit, to delay the agency's approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public's access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week -- versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal -- could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 18, 2007 9:30 AM
On Friday, the first day after Merck's loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor's. In addition, Dr. Reddy's Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA's decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis' generic drug unit, to delay the agency's approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public's access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week -- versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal -- could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).
May 23, 2007 3:06 PM
On Friday, the first day after Merck's loss of patent exclusivity for the statin Zocor, FDA approved three generic versions of the drug, the Wall Street Journal reports. Teva Pharmaceutical Industries and Ranbaxy Pharmaceuticals for the next 180 days will have exclusive rights to sell generic Zocor, generically known as simvastatin. Teva will sell 5-, 10-, 20- and 40-milligram versions, while Ranbaxy will sell an 80-milligram pill. The generic versions are available at a price that is about 30% less than Zocor's. In addition, Dr. Reddy's Laboratories will sell all five dosages of simvastatin under an agreement with Merck to be the authorized generic manufacturer of the drug. FDA's decision came hours after U.S. District Judge Royce Lamberth denied a motion by Sandoz, Novartis' generic drug unit, to delay the agency's approval of generic versions. Lamberth said the delay could damage the finances of Teva and Ranbaxy and could restrict the public's access to affordable drugs (Won Tesoriero/Zhang, Wall Street Jo
urnal, 6/24). FDA estimated that generic versions of Zocor and other generic drugs approved this week -- versions of baldness drug Propecia, prostate drug Proscar and epilepsy treatment Lamictal -- could result in $1 billion per year in savings. Rob Seidman, chief pharmacy officer for WellPoint, said 12 million Medicare Part D beneficiaries who use statins could generate $8.2 billion in savings per year if they switched to generic versions (CQ HealthBeat, 6/23).